Tag - TPTX

The FDA cleared Turning Point Therapeutics’ (NASDAQ:TPTX) IND for TPX-0046, a dual RET and SRC tyrosine kinase inhibitor (TKI) being developed for the treatment of solid tumors. The company plans to initiate a first-in...